prothymosin alpha raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
=== Casimir effect === The Casimir effect is an interaction between disjoint neutral bodies provoked by the fluctuations of the electromagnetic vacuum. Mathematically, it can be explained by considering the normal modes of electromagnetic fields, which explicitly depend on the boundary conditions on the interacting bodies' surfaces. Due to graphene's strong interaction with the electromagnetic field as a one-atom-thick material, the Casimir effect has garnered significant interest.
Tests in community settings without laboratories, which are disease-specific include tests for Chagas disease, cholera, COVID-19, diabetes mellitus, hepatitis B and C, HIV, influenza, malaria, Streptococcal pharyngitis, sickling disorders, syphilis, tuberculosis, visceral leishmaniasis.
=== Protein resurfacing === Protein resurfacing consists of designing a protein's surface while preserving the overall fold, core, and boundary regions of the protein intact. Protein resurfacing is especially useful to alter the binding of a protein to other proteins. One of the most important applications of protein resurfacing was the design of the RSC3 probe to select broadly neutralizing HIV antibodies at the NIH Vaccine Research Center. First, residues outside of the binding interface between the gp120 HIV envelope protein and the formerly discovered b12-antibody were selected to be designed. Then, the sequence spaced was selected based on evolutionary information, solubility, similarity with the wild-type, and other considerations. Then the RosettaDesign software was used to find optimal sequences in the selected sequence space. RSC3 was later used to discover the broadly neutralizing antibody VRC01 in the serum of a long-term HIV-infected non-progressor individual.
Elevated ITGA1 expression correlates with activation of survival pathways and is regulated through a non-coding RNA mechanism involving hsa_circ_0110757, which increases ITGA1 expression by suppressing hsa-miR-1298-5p.
Sources: en.wikipedia.org
Carruthers also studied and reported in 1992 the use of botulinum toxin type-A as a cosmetic treatment.[78] They conducted a study of participants whose only concern was their glabellar forehead wrinkle or furrow. Study participants were otherwise normal. Sixteen of seventeen participants available for follow-up demonstrated a cosmetic improvement. This study was reported at a meeting in 1991. The study for the treatment of glabellar frown lines was published in 1992. This result was subsequently confirmed by other groups (Brin, and the Columbia University group under Monte Keen). The FDA announced regulatory approval of botulinum toxin type A (Botox Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) in 2002 after extensive clinical trials. Well before this, the cosmetic use of botulinum toxin type A became widespread. The results of Botox Cosmetic can last up to four months and may vary with each patient. The US Food and Drug Administration (FDA) approved an alternative product-safety testing method in response to increasing public concern that LD50 testing was required for each batch sold in the market. Botulinum toxin type-A has also been used in the treatment of gummy smiles; the material is injected into the hyperactive muscles of upper lip, which causes a reduction in the upward movement of lip thus resulting in a smile with a less exposure of gingiva.
God bless you." At one point, Singh executed 18 people on one day; these 18 people were among the 58 rioters who killed four prison officers while they were serving their jail terms in a Pulau Senang island prison in 1963. Singh also said that he has hanged seven people within 90 minutes; these seven men were the culprits of the 1971 Gold Bars triple murders, in which a businessman and illegal gold trader was killed together with his driver and colleague over a total of 120 gold bars. Executions peaked between 1994 and 1998; Singapore had the second highest per-capita execution rate in the world during this period, estimated by the United Nations to be 13.83 executions annually per one million people, just behind Turkmenistan with 14.92. Since then, executions have become far less common, with some years having no executions at all. For example, no one was executed in 2012 and 2013, and two persons were executed in 2014. Nevertheless, in the late 2010s, the number of executions has started to increase again: in 2018, 13 people were executed, the most since at least 2003. and four people (including two unreported executions) were hanged in 2019. No one has been executed from the start of 2020 to August 2020, due to the COVID-19 pandemic in Singapore. The first person to be sentenced to death during the COVID-19 pandemic in Singapore was Punithan Genasan, a 37-year-old Malaysian who was also the first to be sentenced to death on 15 May 2020 via a remote court hearing on Zoom. Punithan, who was convicted of drug trafficking, was later acquitted on 31 October 2022 upon appeal.
==== Analysis ==== Analysis of banded chromosomes is done at a microscope by a clinical laboratory specialist in cytogenetics (CLSp(CG)). Generally 20 cells are analyzed which is enough to rule out mosaicism to an acceptable level. The results are summarized and given to a board-certified cytogeneticist for review, and to write an interpretation taking into account the patient's previous history and other clinical findings. The results are then given out reported in an International System for Human Cytogenetic Nomenclature 2009 (ISCN2009)..
== Research == In addition to epilepsy, tiagabine was under formal clinical development for the treatment of anxiety disorders, insomnia, and neuropathic pain. However, development for all of these indications was discontinued. There have also been case reports and case series of tiagabine for treatment of bipolar disorder, though no clinical trials have been conducted. The drug has been studied for treatment of post-traumatic stress disorder (PTSD). It has been studied for treatment of aggression.
The same month, Lineage entered the Spanish marketplace, acquiring cold storage firm Frigorificos de Navarra of Gijón, Spain from Frioastur and, in June 2021, entered the European freight industry with its acquisition of Rotterdam-based UTI Forwarding, and also acquired Kloosterboer Group in Europe, and the cold storage division of Claus Sorensen Group in Denmark. In November 2021, Lineage expanded into the Italian cold storage market with the acquisition of Kantaro SRL. In January 2022, Lineage continued its expansion by acquiring Auscold Logistics in South Australia. In the same month, Lineage also acquired Van Tuyl Logistics, as well as individual locations from H&S Coldstores in Beneden-Leeuwen and Frigocare Rotterdam BV in Rotterdam. In March, Lineage further expanded its network by acquiring MTC Logistics, adding nearly 38 million cubic feet of capacity and more than 113,000 pallet positions in the United States and its presence at key ports along the U.S. East and Gulf Coasts. In April, Lineage acquired VersaCold Logistics to expand its presence in Canada. Later in May, the company acquired Mandai Link Logistics to expand into Singapore. In August, Lineage acquired Cold Storage Nelson in New Zealand. This increased its presence in the Asia-Pacific area. In August 2023, Lineage expanded its European network by acquiring Grupo Fuentes, a Spanish transport and cold store operator. In addition, Lineage strengthened its presence in northern Vietnam through a joint venture with SK Logistics.
Sources: en.wikipedia.org
In a previous research study, the researchers found that the representation of the "outcast" character with mental illness in a movie tends to get negative evaluations from the children. Regarding this, the study found that it could make the children stick with the significant levels of stigmatization in negatively labeling individuals with mental illness even when they grow up. Other research specifically focused on a particular film, Joker, found that the depiction of individuals with mental illness appears to be negative towards the audience. Regarding this, the researchers demonstrated the concerns that the film Joker could aggravate the self-stigma of individuals with mental illness with an emphasis on negative depictions. Another troubling effect is that stereotypical imagery, coupled with the lack of alternative viewpoints, further dissuades mentally ill people from seeking help or treatment. Due to the generally negative view of mental illnesses, regardless of whether or not it is based on truth, those who experience mental illness often feel dejected, embarrassed, or shameful about their diagnoses. These feelings may lead people with mental illnesses to distance themselves from loved ones and often avoid seeking help or treatment due to fear of rejection.
In 2015, the school's name was changed to Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in response to a $30 million donation by the Jacobs family. The Jacobs family includes Jeremy Jacobs, the owner of the Boston Bruins. Before that, in 1987, the school's name was changed to the School of Medicine and Biomedical Sciences in recognition of the basic sciences underpinning medical knowledge. Today, the school enrolls 180 medical students each year, 133 PhD students, 28 MD/PhD students, 71 master's students and 435 undergraduates. Currently, the school is located at the Buffalo Niagara Medical Campus/University at Buffalo's downtown campus as of the Spring of 2018. In 2025, the school partnered with Rochester Institute of Technology (RIT) to offer a pre-admission program to the Jacobs school for eligible RIT students to gain medical training during their undergraduate at RIT.
Nicotinamide adenine dinucleotide (NAD+), a derivative of vitamin B3 (niacin), is an important coenzyme that acts as a hydrogen acceptor. Hundreds of separate types of dehydrogenases remove electrons from their substrates and reduce NAD+ into NADH. This reduced form of the coenzyme is then a substrate for any of the reductases in the cell that need to transfer hydrogen atoms to their substrates. Nicotinamide adenine dinucleotide exists in two related forms in the cell, NADH and NADPH. The NAD+/NADH form is more important in catabolic reactions, while NADP+/NADPH is used in anabolic reactions.
=== Pharmacokinetics === The pharmacokinetics of SR-17018 in rodents have been studied. In mice, it is orally active, showing 69% bioavailability, has an elimination half-life of approximately 6 hours, and efficiently crosses the blood–brain barrier into the central nervous system. The drug has greatly improved bioavailability orally compared to intraperitoneally in mice. Its half-life in mice is longer than that of morphine or oxycodone. Similarly, its duration is longer than that of morphine or fentanyl in mice.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.